Heart failure & cardiomyopathies
Transcriptomic and Proteomic Profiling Shows Dysregulated Immune and Metabolic Pathways in Arrhythmogenic Cardiomyopathy
Authors' conclusion
This integrated transcriptomic and proteomic study of myocardial tissue and plasma from patients with ACM compared with those with DCM and healthy controls, identified key dysregulated pathways, involving immune response, inflammation and oxidative and mitochondrial stress.
Study context
- Population
- Patients with arrhythmogenic cardiomyopathy (ACM) or dilated cardiomyopathy (DCM) and healthy controls; myocardial tissue and plasman = 10/group
- Participants
- 10 / 10 / 10
- Comparison
- ACM vs DCM vs healthy controls
- ACMn = 10
- DCMn = 10
- Healthy controlsn = 10reference
- Outcome
- Myocardial transcriptome and proteome in ACM; detectability of key molecules in plasma and tissue
Main finding
As reported in the abstract
- Dysregulated mRNAs, ACM vs healthy controls
- 3030
- Dysregulated mRNAs, ACM vs DCM
- 120
- Differentially expressed proteins, ACM vs healthy controls
- 206
- Differentially expressed proteins, ACM vs DCM
- 65
- Novel proteins consistently up-regulated at transcript and protein levels (UCHL1, OCIAD1, desmoyokin)
- 3
Original publication
Transcriptomic and Proteomic Profiling Shows Dysregulated Immune and Metabolic Pathways in Arrhythmogenic Cardiomyopathy. ESC Heart Fail. Published 12 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →